227 related articles for article (PubMed ID: 27171855)
1. Use of stereotactic body radiotherapy for prostate cancer in the United States from 2004 through 2012.
Baker BR; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Jul; 122(14):2234-41. PubMed ID: 27171855
[TBL] [Abstract][Full Text] [Related]
2. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
[TBL] [Abstract][Full Text] [Related]
3. Erectile function after stereotactic body radiotherapy for localized prostate cancer.
Dess RT; Hartman HE; Aghdam N; Jackson WC; Soni PD; Abugharib AE; Suy S; Desai NB; Zumsteg ZS; Mehra R; Morgan TM; Feng FY; Hamstra DA; Schipper MJ; Collins SP; Spratt DE
BJU Int; 2018 Jan; 121(1):61-68. PubMed ID: 28710895
[TBL] [Abstract][Full Text] [Related]
4. Travel distance and stereotactic body radiotherapy for localized prostate cancer.
Mahal BA; Chen YW; Sethi RV; Padilla OA; Yang DD; Chavez J; Muralidhar V; Hu JC; Feng FY; Hoffman KE; Martin NE; Spratt DE; Yu JB; Orio PF; Nguyen PL
Cancer; 2018 Mar; 124(6):1141-1149. PubMed ID: 29231964
[TBL] [Abstract][Full Text] [Related]
5. Predictors of multidomain decline in health-related quality of life after stereotactic body radiation therapy (SBRT) for prostate cancer.
Dess RT; Jackson WC; Suy S; Soni PD; Lee JY; Abugharib AE; Zumsteg ZS; Feng FY; Hamstra DA; Collins SP; Spratt DE
Cancer; 2017 May; 123(9):1635-1642. PubMed ID: 28001303
[TBL] [Abstract][Full Text] [Related]
6. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
Jacobs BL; Yabes JG; Lopa SH; Heron DE; Chang CH; Schroeck FR; Bekelman JE; Kahn JM; Nelson JB; Barnato AE
Cancer; 2017 Aug; 123(15):2945-2954. PubMed ID: 28301689
[TBL] [Abstract][Full Text] [Related]
7. Stereotactic body radiation therapy (SBRT) for prostate cancer in men with large prostates (≥50 cm(3)).
Janowski E; Chen LN; Kim JS; Lei S; Suy S; Collins B; Lynch J; Dritschilo A; Collins S
Radiat Oncol; 2014 Nov; 9():241. PubMed ID: 25398516
[TBL] [Abstract][Full Text] [Related]
8. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements.
Gill BS; Lin JF; Krivak TC; Sukumvanich P; Laskey RA; Ross MS; Lesnock JL; Beriwal S
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1083-90. PubMed ID: 25216857
[TBL] [Abstract][Full Text] [Related]
9. Stereotactic body radiotherapy as boost for organ-confined prostate cancer.
Katz AJ; Santoro M; Ashley R; Diblasio F; Witten M
Technol Cancer Res Treat; 2010 Dec; 9(6):575-82. PubMed ID: 21070079
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer.
Oermann EK; Slack RS; Hanscom HN; Lei S; Suy S; Park HU; Kim JS; Sherer BA; Collins BT; Satinsky AN; Harter KW; Batipps GP; Constantinople NL; Dejter SW; Maxted WC; Regan JB; Pahira JJ; McGeagh KG; Jha RC; Dawson NA; Dritschilo A; Lynch JH; Collins SP
Technol Cancer Res Treat; 2010 Oct; 9(5):453-62. PubMed ID: 20815416
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response.
Jabbari S; Weinberg VK; Kaprealian T; Hsu IC; Ma L; Chuang C; Descovich M; Shiao S; Shinohara K; Roach M; Gottschalk AR
Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):228-34. PubMed ID: 21183287
[TBL] [Abstract][Full Text] [Related]
12. A dosimetric comparison of ultra-hypofractionated passively scattered proton radiotherapy and stereotactic body radiotherapy (SBRT) in the definitive treatment of localized prostate cancer.
Kole TP; Nichols RC; Lei S; Wu B; Huh SN; Morris CG; Lee S; Tong M; Mendenhall NP; Dritschilo A; Collins SP
Acta Oncol; 2015 Jun; 54(6):825-31. PubMed ID: 25227898
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported urinary incontinence following stereotactic body radiation therapy (SBRT) for clinically localized prostate cancer.
Chen LN; Suy S; Wang H; Bhagat A; Woo JA; Moures RA; Kim JS; Yung TM; Lei S; Collins BT; Kowalczyk K; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2014 Jun; 9():148. PubMed ID: 24966110
[TBL] [Abstract][Full Text] [Related]
14. Utilizing time-driven activity-based costing to understand the short- and long-term costs of treating localized, low-risk prostate cancer.
Laviana AA; Ilg AM; Veruttipong D; Tan HJ; Burke MA; Niedzwiecki DR; Kupelian PA; King CR; Steinberg ML; Kundavaram CR; Kamrava M; Kaplan AL; Moriarity AK; Hsu W; Margolis DJ; Hu JC; Saigal CS
Cancer; 2016 Feb; 122(3):447-55. PubMed ID: 26524087
[TBL] [Abstract][Full Text] [Related]
15. Is robotic arm stereotactic body radiation therapy “virtual high dose ratebrachytherapy” for prostate cancer? An analysis of comparative effectiveness using published data [corrected].
Zaorsky NG; Hurwitz MD; Dicker AP; Showalter TN; Den RB
Expert Rev Med Devices; 2015 May; 12(3):317-27. PubMed ID: 25540018
[TBL] [Abstract][Full Text] [Related]
16. Stereotactic body radiation therapy for prostate cancer: is the technology ready to be the standard of care?
Zaorsky NG; Studenski MT; Dicker AP; Gomella L; Den RB
Cancer Treat Rev; 2013 May; 39(3):212-8. PubMed ID: 23218442
[TBL] [Abstract][Full Text] [Related]
17. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment.
Fuller DB; Wurzer J; Shirazi R; Bridge SS; Law J; Mardirossian G
Pract Radiat Oncol; 2015; 5(6):e615-23. PubMed ID: 26059509
[TBL] [Abstract][Full Text] [Related]
18. Stereotactic Body Radiotherapy versus Low Dose Rate Brachytherapy for Localised Prostate Cancer: a Cost-Utility Analysis.
Helou J; Torres S; Musunuru HB; Raphael J; Cheung P; Vesprini D; Chung HT; D'Alimonte L; Krahn M; Morton G; Loblaw A
Clin Oncol (R Coll Radiol); 2017 Nov; 29(11):718-731. PubMed ID: 28916284
[TBL] [Abstract][Full Text] [Related]
19. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB
Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426
[TBL] [Abstract][Full Text] [Related]
20. Stereotactic Body Radiation Therapy, Intensity-Modulated Radiation Therapy, and Brachytherapy Boost Modalities in Invasive Cervical Cancer: A Study of the National Cancer Data Base.
OʼDonnell B; Shiao JC; Pezzi TA; Waheed N; Sharma S; Bonnen MD; Ludwig MS
Int J Gynecol Cancer; 2018 Mar; 28(3):563-574. PubMed ID: 29324547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
